» Articles » PMID: 37932837

Fabrication of a Three-dimensional Bone Marrow Niche-like Acute Myeloid Leukemia Disease Model by an Automated and Controlled Process Using a Robotic Multicellular Bioprinting System

Abstract

Background: Acute myeloid leukemia (AML) is a hematological malignancy that remains a therapeutic challenge due to the high incidence of disease relapse. To better understand resistance mechanisms and identify novel therapies, robust preclinical models mimicking the bone marrow (BM) microenvironment are needed. This study aimed to achieve an automated fabrication process of a three-dimensional (3D) AML disease model that recapitulates the 3D spatial structure of the BM microenvironment and applies to drug screening and investigational studies.

Methods: To build this model, we investigated a unique class of tetramer peptides with an innate ability to self-assemble into stable hydrogel. An automated robotic bioprinting process was established to fabricate a 3D BM (niche-like) multicellular AML disease model comprised of leukemia cells and the BM's stromal and endothelial cellular fractions. In addition, monoculture and dual-culture models were also fabricated. Leukemia cell compatibility, functionalities (in vitro and in vivo), and drug assessment studies using our model were performed. In addition, RNAseq and gene expression analysis using TaqMan arrays were also performed on 3D cultured stromal cells and primary leukemia cells.

Results: The selected peptide hydrogel formed a highly porous network of nanofibers with mechanical properties similar to the BM extracellular matrix. The robotic bioprinter and the novel quadruple coaxial nozzle enabled the automated fabrication of a 3D BM niche-like AML disease model with controlled deposition of multiple cell types into the model. This model supported the viability and growth of primary leukemic, endothelial, and stromal cells and recapitulated cell-cell and cell-ECM interactions. In addition, AML cells in our model possessed quiescent characteristics with improved chemoresistance attributes, resembling more the native conditions as indicated by our in vivo results. Moreover, the whole transcriptome data demonstrated the effect of 3D culture on enhancing BM niche cell characteristics. We identified molecular pathways upregulated in AML cells in our 3D model that might contribute to AML drug resistance and disease relapse.

Conclusions: Our results demonstrate the importance of developing 3D biomimicry models that closely recapitulate the in vivo conditions to gain deeper insights into drug resistance mechanisms and novel therapy development. These models can also improve personalized medicine by testing patient-specific treatments.

Citing Articles

Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.

Vlahopoulos S, Varisli L, Zoumpourlis P, Spandidos D, Zoumpourlis V Int J Oncol. 2024; 65(6).

PMID: 39513593 PMC: 11575927. DOI: 10.3892/ijo.2024.5703.

References
1.
Wang Z, Wu D, Zou J, Zhou Q, Liu W, Zhang W . Development of demineralized bone matrix-based implantable and biomimetic microcarrier for stem cell expansion and single-step tissue-engineered bone graft construction. J Mater Chem B. 2020; 5(1):62-73. DOI: 10.1039/c6tb02414a. View

2.
Griessinger E, Anjos-Afonso F, Pizzitola I, Rouault-Pierre K, Vargaftig J, Taussig D . A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med. 2014; 3(4):520-9. PMC: 3973718. DOI: 10.5966/sctm.2013-0166. View

3.
Kremer K, Dudakovic A, McGee-Lawrence M, Philips R, Hess A, Smith B . Osteoblasts protect AML cells from SDF-1-induced apoptosis. J Cell Biochem. 2014; 115(6):1128-37. PMC: 4161028. DOI: 10.1002/jcb.24755. View

4.
Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth E, Watson K . Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010; 12(5):615-25. DOI: 10.3109/14653241003631815. View

5.
Banerjee C, Javed A, Choi J, Green J, Rosen V, van Wijnen A . Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology. 2001; 142(9):4026-39. DOI: 10.1210/endo.142.9.8367. View